Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ATM negative||Advanced Solid Tumor||predicted - sensitive||BAY1895344||Phase I||Actionable||In a Phase I trial, BAY 1895344 treatment resulted in an objective response rate of 30.7% (4/13) in patients with advanced solid tumors, all responders harbored ATM protein expression loss and/or ATM mutations (J Clin Oncol 37, 2019 (suppl; abstr 3007); NCT03188965).||detail...|
|ATM negative||stomach cancer||no benefit||PARP Inhibitor (Pan)||Olaparib + Paclitaxel||Phase III||Actionable||In a Phase III trial (GOLD), addition of Lynparza (olaparib) to Taxol (paclitaxel) did not significantly improve overall survival (12.0 vs 10.0 months, HR=0.73, p=0.25) compared to Taxol (paclitaxel) alone in Asian patients with ATM-negative gastric cancer (PMID: 29103871; NCT01924533).||29103871|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|